BASKHANBIOPharma바스칸바이오제약

BASKHANBIOPharma is a small KONEX-listed pharma maker whose shares have fallen about 31% over the past year, with no annual financials in the data supplied.

The company makes prescription and over-the-counter drugs and medical devices, with a focus on products used around surgery, and prescription drugs were about 72% of 2025 sales. Its share price is ₩3,555, roughly 42% below its 52-week high of ₩6,090, and its market value is about ₩25B. The data includes no annual financials, trailing earnings, or valuation multiples, so the current financial position cannot be assessed from it.

What stands out

• Shares are down 30.6% over one year and 11.1% over three months, though up 1.9% over one month.
• Market capitalisation is about ₩25B, far smaller than the large listed peers shown, such as Samsung Biologics at about ₩67.9T.
• The data shows no annual financials, trailing results, P/E, P/B or EV/EBITDA for the company, so valuation cannot be compared with peers on earnings.
• Recent filings are mostly routine: an annual report for December 2025, an AGM result in March, investor relations events, and a change to its designated adviser agreement in September.
• No news headlines were found in the data, and no foreign or institutional buying appears in the 20-day flows; retail investors were net sellers by about ₩25M.

What to watch

• Upcoming results and any annual financial statements, which are not yet in the data supplied.
• The planned expansion into non-reimbursed drugs, injectables and a hemostatic device, which the profile mentions but the data does not quantify.
• The September change to the designated adviser agreement, which the filing title alone does not explain.